Abstract
Although efavirenz and lopinavir/ritonavir(r) are both recommended antiretroviral agents in antiretroviral-naïve HIV-infected patients, there are few randomized comparisons of their efficacy and tolerability. A multicenter and randomized study was performed including 126 antiretroviral-naïve patients, randomly assigned to efavirenz+Kivexa (n=63) or lopinavir/r+Kivexa (n=63). Efficacy endpoints were the percentage of patients with HIV-RNA < or =50 copies/mL at week 48 and CD4 recovery. Safety was assessed by comparing toxicity and discontinuations. Statistical analyses were performed on an intention-to-treat (ITT) basis (Missing=Failure). At week 48, 56.7% of patients in the efavirenz and 63.2% in the lopinavir/r groups showed HIV-1 RNA <50 copies/mL (P=0.770) (intention-to-treat analysis; Missing=Failure). Only 1 (1.53%) patient from each group experienced virological failure. CD4 values increased in both groups (298 cells in the efavirenz group, P=0.001; 249 cells in the lopinavir/r group, P=0.002; P=0.126 between groups). HDL-cholesterol only increased in the efavirenz group (from 39+/-12 mg/dL to 49+/-11; P=0.001). Discontinuations were more frequent in the lopinavir/r group (36.5% versus 28.5%; P=0.193), but more patients w...Continue Reading
References
Aug 16, 2001·AIDS·J A BartlettF Rousseau
Oct 2, 2001·AIDS·A C FriedlUNKNOWN Swiss Cohort Study
Jul 20, 2002·AIDS·Jose R ArribasUNKNOWN EfaVIP Cohort Study Group
Apr 13, 2004·AIDS·Eugenia NegredoBonaventura Clotet
Apr 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Federico PulidoUNKNOWN EfaVIP Cohort Study Group
Dec 4, 2004·AIDS·Roberto ManfrediFrancesco Chiodo
May 21, 2005·AIDS·Elizabeth J PhillipsNeil H Shear
Jun 28, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Clotilde AllavenaUNKNOWN Bitherapy Kaletra-Sustiva Study Group
Oct 18, 2005·AIDS·Michael P DubéKathleen Mulligan
Aug 28, 2007·HIV Clinical Trials·John A BartlettJoseph B Quinn
Dec 22, 2007·AIDS·Karen TashimaVictoria Wirtz
Mar 22, 2008·The Journal of Antimicrobial Chemotherapy·Pere DomingoMyriam Garrido
May 16, 2008·The New England Journal of Medicine·Sharon A RiddlerUNKNOWN AIDS Clinical Trials Group Study A5142 Team
Citations
May 25, 2013·The Journal of Infectious Diseases·Andrew HillRavindra K Gupta
Mar 24, 2011·The Pediatric Infectious Disease Journal·Pierre FrangeMarie-Laure Chaix
Jan 2, 2014·AIDS Research and Human Retroviruses·Berta TorresFelipe Garcia
Apr 17, 2012·International Journal of Hepatology·Manuela G NeumanCharles Parry
Sep 17, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C TortiI Frank
Apr 20, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Álvaro H BorgesJens D Lundgren
Sep 5, 2014·PloS One·Dipen A PatelGarrett Nichols
May 2, 2015·PloS One·Joanna KrystAndrzej Pilc
Oct 30, 2016·The Lancet. HIV·Steve KantersEdward J Mills
Oct 8, 2016·BMC Infectious Diseases·Jaime GalindoXimena Galindo-Orrego
Jun 1, 2018·Viruses·Vicente SorianoJose V Fernandez-Montero
Jul 14, 2018·HIV Medicine·S GallienE Lazaro
Feb 12, 2010·Journal of Clinical Pharmacology·Edgar T OvertonEdward P Acosta
Dec 15, 2015·PloS One·Nicole Hassoun
Mar 13, 2018·Open Forum Infectious Diseases·Yanink Caro-VegaJuan G Sierra-Madero
Dec 1, 2011·The Journal of Antimicrobial Chemotherapy·José A Pérez-MolinaSantiago Moreno
Apr 9, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Nathan FordAlexandra Calmy
Jun 9, 2020·Allergy·Aslı GelincikMaria Jose Torres
May 31, 2019·BMC Infectious Diseases·Sonya J SnedecorYogesh S Punekar
Jul 19, 2012·Clinical Pharmacology and Therapeutics·M SiccardiD Back